{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:49:44Z","timestamp":1792788584067,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main","id":[{"id":"https:\/\/ror.org\/04cvxnb49","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world adjuvant systemic therapy (AST) use for eligible renal cell carcinoma (RCC) patients remains insufficiently characterized in the contemporary treatment era. In particular, it is unclear whether treatment allocation reflects established high-risk tumor characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the Surveillance, Epidemiology, and End Results (SEER) database, the study identified patients eligible for AST after nephrectomy (2018\u20132022). Temporal trends in AST use were assessed. Multivariable logistic regression models tested associations between histopathologic high-risk features (T4 stage, tumor grade 4, and N1\u20132 stage) and AST use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 6,497 eligible patients, 1,163 (18%) received AST. Annual proportions of AST increased from 13% in 2018 to 36% in 2022. Higher AST use was independently predicted by T4 stage (33% vs. 18%; odds ratio [OR], 1.68;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.006), tumor grade 4 (28% vs. 15%; OR, 1.94;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), and N1\u20132 stage (36% vs. 17%; OR, 2.57;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Patients who had any of these three high-risk features were more likely to receive AST than those who did not (28% vs. 14%; OR, 2.27;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Moreover, a stepwise increase in AST use was observed with an increasing number of high-risk features (one: 26% [OR, 2.09;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001], two: 37% [OR, 3.56;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001], three: 40% [OR, 4.04;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.014]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Only a minority of eligible RCC patients received AST after nephrectomy. However, the proportion of AST use increased over time. Use of AST was strongly associated with adverse tumor characteristics. A stratification according to the number of high-risk features showed a dose-response effect. Nevertheless, AST use remained limited even among patients at the highest risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20341-9","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:52:36Z","timestamp":1785858756000},"page":"10480-10486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk-Adapted Use of Adjuvant Systemic Therapy After Nephrectomy for Renal Cell Carcinoma: A Population-Based Study in the Post-approval Era"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5715-9965","authenticated-orcid":false,"given":"Maximilian","family":"Filzmayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Petix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan A.","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Carmignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Micali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"He\u00df-Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Humke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K.-H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"20341_CR1","unstructured":"European Association of Urology: EAU Guidelines. Edition presented at the EAU Annual Congress in London, 2026."},{"key":"20341_CR2","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Kidney Cancer. Version 3, 2025."},{"key":"20341_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/JU.0000000000001912","volume":"206","author":"SC Campbell","year":"2021","unstructured":"Campbell SC, Uzzo RG, Karam JA, et al. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline. J Urol. 2021;206:209\u201318.","journal-title":"J Urol."},{"key":"20341_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/OTT.S393296","volume":"16","author":"DM Buller","year":"2023","unstructured":"Buller DM, Antony M, Ristau BT. Adjuvant therapy for high-risk localized renal cell carcinoma: current landscape and future direction. Onco Targets Ther. 2023;16:49\u201364.","journal-title":"Onco Targets Ther."},{"key":"20341_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41585-022-00666-2","volume":"20","author":"KN Fitzgerald","year":"2023","unstructured":"Fitzgerald KN, Motzer RJ, Lee CH. Adjuvant therapy options in renal cell carcinoma: targeting the metastatic cascade. Nat Rev Urol. 2023;20:179\u201393.","journal-title":"Nat Rev Urol."},{"key":"20341_CR6","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","volume":"375","author":"A Ravaud","year":"2016","unstructured":"Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375:2246\u201354.","journal-title":"N Engl J Med."},{"key":"20341_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2017.09.008","volume":"73","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Ravaud A, Patard JJ, et al. Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results. Eur Urol. 2018;73:62\u20138.","journal-title":"Eur Urol."},{"key":"20341_CR8","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683\u201394.","journal-title":"N Engl J Med."},{"key":"20341_CR9","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","volume":"390","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Tomczak P, Park SH, et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med. 2024;390:1359\u201371.","journal-title":"N Engl J Med."},{"key":"20341_CR10","doi-asserted-by":"publisher","first-page":"16731","DOI":"10.18632\/oncotarget.24675","volume":"9","author":"T Chandrasekar","year":"2018","unstructured":"Chandrasekar T, Klaassen Z, Goldberg H, et al. High competing risks minimize real-world utility of adjuvant targeted therapy in renal cell carcinoma: a population-based analysis. Oncotarget. 2018;9:16731\u201343.","journal-title":"Oncotarget."},{"issue":"604","key":"20341_CR11","first-page":"e601","volume":"38","author":"NH Chakiryan","year":"2020","unstructured":"Chakiryan NH, Acevedo AM, Garzotto MA, et al. Survival outcomes and practice trends for off-label use of adjuvant targeted therapy in high-risk locoregional renal cell carcinoma. Urol Oncol. 2020;38(604):e601\u20137.","journal-title":"Urol Oncol."},{"key":"20341_CR12","doi-asserted-by":"crossref","unstructured":"Howard JM, Nandy K, Woldu SL, et al. Demographic factors associated with non-guideline\u2013based treatment of kidney cancer in the United States. JAMA Network Open. 2021;4(6):e2112813.","DOI":"10.1001\/jamanetworkopen.2021.12813"},{"key":"20341_CR13","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2025, based on the November 2024 submission."},{"key":"20341_CR14","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","volume":"82","author":"H Moch","year":"2022","unstructured":"Moch H, Amin MB, Berney DM, et al. The 2022 World Health organization classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2022;82:458\u201368.","journal-title":"Eur Urol."},{"key":"20341_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41585-020-00382-9","volume":"17","author":"KA Blum","year":"2020","unstructured":"Blum KA, Gupta S, Tickoo SK, et al. Sarcomatoid renal cell carcinoma: biology, natural history, and management. Nat Rev Urol. 2020;17:659\u201378.","journal-title":"Nat Rev Urol."},{"key":"20341_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2026.111924","volume":"52","author":"M Filzmayer","year":"2026","unstructured":"Filzmayer M, Quarta L, Petix M, et al. Rates of adjacent organ invasion in non-metastatic renal cell carcinoma: a population-based study. Eur J Surg Oncol. 2026;52:111924.","journal-title":"Eur J Surg Oncol."},{"key":"20341_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.5489\/cuaj.5187","volume":"12","author":"PI Karakiewicz","year":"2018","unstructured":"Karakiewicz PI, Zaffuto E, Kapoor A, et al. Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: a comprehensive analysis of the literature and meta-analysis of randomized controlled trials. Can Urol Assoc J. 2018;12:173\u201380.","journal-title":"Can Urol Assoc J."},{"key":"20341_CR18","doi-asserted-by":"crossref","unstructured":"Karakiewicz PI, Lewinshtein DJ, Chun FK, et al. Tumor size improves the accuracy of TNM predictions in patients with renal cancer. Eur Urol. 2006;50:521\u20138;discussion 529.","DOI":"10.1016\/j.eururo.2006.02.034"},{"key":"20341_CR19","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806\u20138.","journal-title":"BMJ."},{"key":"20341_CR20","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s00345-025-05992-9","volume":"43","author":"M de Angelis","year":"2025","unstructured":"de Angelis M, Pellegrino F, Scilipoti P, et al. Real-world impact of cisplatin-based neoadjuvant chemotherapy on bladder cancer survival: a 20-year study. World J Urol. 2025;43:636.","journal-title":"World J Urol."},{"key":"20341_CR21","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/bju.16780","volume":"136","author":"M Longoni","year":"2025","unstructured":"Longoni M, Scilipoti P, De Angelis M, et al. Contemporary outcomes in non-muscle-invasive bladder cancer: a large European multicentre study. BJU Int. 2025;136:826\u201334.","journal-title":"BJU Int."},{"key":"20341_CR22","doi-asserted-by":"publisher","first-page":"7229","DOI":"10.1245\/s10434-024-15814-8","volume":"31","author":"F Di Bello","year":"2024","unstructured":"Di Bello F, Jannello LMI, Siech C, et al. Adjuvant systemic therapy improved survival after radical nephroureterectomy for upper-tract urothelial carcinoma. Ann Surg Oncol. 2024;31:7229\u201336.","journal-title":"Ann Surg Oncol."},{"key":"20341_CR23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/00000478-200404000-00002","volume":"28","author":"JC Cheville","year":"2004","unstructured":"Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004;28:435\u201341.","journal-title":"Am J Surg Pathol."},{"key":"20341_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/00000478-198210000-00007","volume":"6","author":"SA Fuhrman","year":"1982","unstructured":"Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655\u201363.","journal-title":"Am J Surg Pathol."},{"key":"20341_CR25","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.euf.2025.05.023","volume":"11","author":"QC Le","year":"2025","unstructured":"Le QC, Marmiroli A, Longoni M, et al. Life expectancy of renal cell carcinoma with variant histology. Eur Urol Focus. 2025;11:810\u201320.","journal-title":"Eur Urol Focus."},{"key":"20341_CR26","unstructured":"Di Bello F, Gallioli A, Uleri A, et al. Kidney-sparing treatments for local recurrence in renal cell tumours after partial nephrectomy or focal therapy: a systematic review. Eur Urol Focus. 2025;S2405-4569(25)00356-6."},{"key":"20341_CR27","doi-asserted-by":"crossref","unstructured":"Filzmayer M, Polverino F, Petix M, et al. Racial\/ethnic differences in time to nephrectomy and its association with cancer-specific mortality in localized renal cell carcinoma. Int Urol Nephrol. 2026.","DOI":"10.1007\/s11255-026-05141-0"},{"issue":"46","key":"20341_CR28","first-page":"e41","volume":"32","author":"M Bianchi","year":"2014","unstructured":"Bianchi M, Gandaglia G, Trinh QD, et al. A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma. Urol Oncol. 2014;32(46):e41\u20137.","journal-title":"Urol Oncol."},{"key":"20341_CR29","doi-asserted-by":"crossref","unstructured":"Filzmayer M, Polverino F, Petix M, et al. Survival differences of localized papillary renal cell carcinoma in African Americans vs European Americans. J Racial Ethn Health Disparities. 2026.","DOI":"10.1007\/s40615-026-03038-3"},{"key":"20341_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.clgc.2023.10.011","volume":"22","author":"A Baudo","year":"2024","unstructured":"Baudo A, Incesu RB, Morra S, et al. Other-cause mortality, according to partial vs radical nephrectomy: age and stage analyses. Clin Genitourin Cancer. 2024;22:181\u20138.","journal-title":"Clin Genitourin Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20341-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20341-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20341-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:24:20Z","timestamp":1792207460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20341-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["20341"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20341-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflict of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Ethical approval for this study and requirement for informed consent were waived by the Internal Review Board (Comit\u00e9 d\u2019\u00e9thique \u00e0 la recherche du Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al) due to the use of anonymized data from the SEER database.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}